Developed in-house by combining expertise in small molecules, devices, and biosimilars, Sandoz intends for its tirzepatide to be the first generic rival to Mounjaro/Zepbound autoinjectors.
Developed in-house by combining expertise in small molecules, devices, and biosimilars, Sandoz intends for its tirzepatide to be the first generic rival to Mounjaro/Zepbound autoinjectors.